Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication
The STudy of Atherosclerosis with Ramipril and Rosiglitazone (STARR) is a multi-centre, international, randomised controlled clinical trial with a 2x2 factorial design, that will evaluate the effects of ramipril and rosiglitazone on atherosclerosis progression, as determined by B-mode carotid ultrasound. This study is designed as a sub-study of DREAM. To date, the study has enrolled 1,400 participants who will be followed for an average of 3.75 years. The study is co-ordinated by the Canadian Cardiovascular Collaboration (CCC) at McMaster University, Hamilton, Canada. European sites are managed by the EuroDREAM project office at the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK.